Inhibition of CK2α down-regulates Notch1 signalling in lung cancer cells

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 7, 2013, Pages 854-862

  Zhang, Shulin ^a,b   Long, Hao ^c   Yang, Yi Lin ^a   Wang, Yucheng ^a   Hsieh, David ^a   Li, Weiming ^b   Au, Alfred ^d   Stoppler, Hubert J ^d   Xu, Zhidong ^a   Jablons, David M ^a   You, Liang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer stem cell; CD44 + CD24 ; CK2 ; Lung cancer; Notch1

Indexed keywords

5 (3 CHLOROPHENYLAMINO)BENZO(C)(2,6)NAPHTHYRIDINE 8 CARBOXYLIC ACID; 5-(3-CHLOROPHENYLAMINO)BENZO(C)(2,6)NAPHTHYRIDINE-8-CARBOXYLIC ACID; CASEIN KINASE II; CD24 ANTIGEN; DNA; HERMES ANTIGEN; NAPHTHYRIDINE DERIVATIVE; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; CANCER STEM CELL; CD44 + /CD24-; CK2Α; CYTOLOGY; DOSE RESPONSE; DOWN REGULATION; DRUG ANTAGONISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG TUMOR; METABOLISM; NOTCH1; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CANCER STEM CELL; CD44 + /CD24-; CK2Α; LUNG CANCER; NOTCH1;

ANTIGENS, CD24; ANTIGENS, CD44; CASEIN KINASE II; CELL LINE, TUMOR; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NAPHTHYRIDINES; NEOPLASTIC STEM CELLS; PHENOTYPE; RECEPTOR, NOTCH1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84880778731     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12068     Document Type: Article

References (41)

1. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003; 17: 349-68.
2. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta. 2010; 1804: 499-504.
3. Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta. 2008; 1784: 33-47.
4. Dominguez I, Sonenshein GE, Seldin DC. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signalling: linking development and cancer. Cell Mol Life Sci. 2009; 66: 1850-7.
5. Trembley JH, Wang G, Unger G, et al. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci. 2009; 66: 1858-67.
6. Piazza FA, Ruzzene M, Gurrieri C, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood. 2006; 108: 1698-707.
7. Wang G, Ahmad KA, Harris NH, et al. Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells. Mol Cell Biochem. 2008; 316: 91-7.
8. Martins LR, Lucio P, Silva MC, et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood. 2010; 116: 2724-31.
9. Laramas M, Pasquier D, Filhol O, et al. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer. 2007; 43: 928-34.
10. Kim JS, Eom JI, Cheong JW, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res. 2007; 13: 1019-28.
11. Lin KY, Fang CL, Chen Y, et al. Overexpression of nuclear protein kinase CK2 Beta subunit and prognosis in human gastric carcinoma. Ann Surg Oncol. 2010; 17: 1695-702.
12. Guo C, Yu S, Davis AT, et al. Nuclear matrix targeting of the protein kinase CK2 signal as a common downstream response to androgen or growth factor stimulation of prostate cancer cells. Cancer Res. 1999; 59: 1146-51.
13. Buchou T, Vernet M, Blond O, et al. Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol. 2003; 23: 908-15.
14. Ahmad KA, Wang G, Unger G, et al. Protein kinase CK2-a key suppressor of apoptosis. Adv Enzyme Regul. 2008; 48: 179-87.
15. Guerra B. Protein kinase CK2 subunits are positive regulators of AKT kinase. Int J Oncol. 2006; 28: 685-93.
16. Zhang S, Wang Y, Mao JH, et al. Inhibition of CK2alpha down-regulates Hedgehog/Gli signalling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS ONE. 2012; 7: e38996.
17. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch signalling. Science. 1995; 268: 225-32.
18. Jeffries S, Robbins DJ, Capobianco AJ. Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line. Mol Cell Biol. 2002; 22: 3927-41.
19. Westhoff B, Colaluca IN, D'Ario G, et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA. 2009; 106: 22293-8.
20. McGowan PM, Simedrea C, Ribot EJ, et al. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res. 2011; 9: 834-44.
21. Li T, Li H, Wang Y, et al. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. J Pathol. 2011; 223: 519-30.
22. Hsieh JJ, Zhou S, Chen L, et al. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci USA. 1999; 96: 23-8.
23. Dhoot GK, Gustafsson MK, Ai X, et al. Regulation of Wnt signalling and embryo patterning by an extracellular sulfatase. Science. 2001; 293: 1663-6.
24. Krebs LT, Deftos ML, Bevan MJ, et al. The Nrarp gene encodes an ankyrin-repeat protein that is transcriptionally regulated by the notch signalling pathway. Dev Biol. 2001; 238: 110-9.
25. Pierre F, Chua PC, O'Brien SE, et al. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2, 6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2011; 54: 635-54.
26. Sarno S, Reddy H, Meggio F, et al. Selectivity of 4, 5, 6, 7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 2001; 496: 44-8.
27. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003; 100: 3983-8.
28. Meng E, Long B, Sullivan P, et al. CD44 +/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis. 2012; 29: 939-48.
29. Du Z, Li J, Wang L, et al. Overexpression of DeltaNp63alpha induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway. Cancer Sci. 2010; 101: 2417-24.
30. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signalling: cell fate control and signal integration in development. Science. 1999; 284: 770-6.
31. Wang NJ, Sanborn Z, Arnett KL, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA. 2011; 108: 17761-6.
32. Eliasz S, Liang S, Chen Y, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene. 2010; 29: 2488-98.
33. Galluzzo P, Bocchetta M. Notch signalling in lung cancer. Expert Rev Anticancer Ther. 2011; 11: 533-40.
34. Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 2010; 9: 3126-36.
35. Obenauer JC, Cantley LC, Yaffe MB. Scansite 2.0: proteome-wide prediction of cell signalling interactions using short sequence motifs. Nucleic Acids Res. 2003; 31: 3635-41.
36. Venugopalan SR, Li X, Amen MA, et al. Hierarchical interactions of homeodomain and forkhead transcription factors in regulating odontogenic gene expression. J Biol Chem. 2011; 286: 21372-83.
37. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signalling pathways during carcinogenesis. Stem Cell Rev. 2007; 3: 30-8.
38. Leung EL, Fiscus RR, Tung JW, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS ONE. 2010; 5: e14062.
39. Pierre F, Chua PC, O'Brien SE, et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem. 2011; 356: 37-43.
40. Perea SE, Baladron I, Garcia Y, et al. CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research. Mol Cell Biochem. 2011; 356: 45-50.
41. Wirkner U, Voss H, Lichter P, et al. Human protein kinase CK2 genes. Cell Mol Biol Res. 1994; 40: 489-99.